Eris Lifesciences Limited

NSEI:ERIS Rapporto sulle azioni

Cap. di mercato: ₹162.5b

Eris Lifesciences Gestione

Gestione criteri di controllo 4/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Amit Bakshi

Amministratore delegato

₹48.8m

Compenso totale

Percentuale dello stipendio del CEO35.9%
Mandato del CEO18yrs
Proprietà del CEO42.9%
Durata media del management8.3yrs
Durata media del Consiglio di amministrazione4.3yrs

Aggiornamenti recenti sulla gestione

Eris Lifesciences Limited's (NSE:ERIS) CEO Compensation Looks Acceptable To Us And Here's Why

Sep 19
Eris Lifesciences Limited's (NSE:ERIS) CEO Compensation Looks Acceptable To Us And Here's Why

Recent updates

What You Can Learn From Eris Lifesciences Limited's (NSE:ERIS) P/E

Jan 07
What You Can Learn From Eris Lifesciences Limited's (NSE:ERIS) P/E

Here's Why Eris Lifesciences (NSE:ERIS) Can Manage Its Debt Responsibly

Nov 21
Here's Why Eris Lifesciences (NSE:ERIS) Can Manage Its Debt Responsibly

Eris Lifesciences Limited Just Missed EPS By 8.6%: Here's What Analysts Think Will Happen Next

Oct 30
Eris Lifesciences Limited Just Missed EPS By 8.6%: Here's What Analysts Think Will Happen Next

A Look At The Fair Value Of Eris Lifesciences Limited (NSE:ERIS)

Oct 15
A Look At The Fair Value Of Eris Lifesciences Limited (NSE:ERIS)

Eris Lifesciences Limited's (NSE:ERIS) CEO Compensation Looks Acceptable To Us And Here's Why

Sep 19
Eris Lifesciences Limited's (NSE:ERIS) CEO Compensation Looks Acceptable To Us And Here's Why

Earnings Tell The Story For Eris Lifesciences Limited (NSE:ERIS) As Its Stock Soars 27%

Sep 03
Earnings Tell The Story For Eris Lifesciences Limited (NSE:ERIS) As Its Stock Soars 27%

Earnings Update: Eris Lifesciences Limited (NSE:ERIS) Just Reported Its First-Quarter Results And Analysts Are Updating Their Forecasts

Aug 05
Earnings Update: Eris Lifesciences Limited (NSE:ERIS) Just Reported Its First-Quarter Results And Analysts Are Updating Their Forecasts

Eris Lifesciences (NSE:ERIS) Seems To Use Debt Quite Sensibly

Aug 04
Eris Lifesciences (NSE:ERIS) Seems To Use Debt Quite Sensibly

Estimating The Intrinsic Value Of Eris Lifesciences Limited (NSE:ERIS)

Jul 13
Estimating The Intrinsic Value Of Eris Lifesciences Limited (NSE:ERIS)

Eris Lifesciences Limited (NSE:ERIS) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?

May 24
Eris Lifesciences Limited (NSE:ERIS) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?

Why We're Not Concerned About Eris Lifesciences Limited's (NSE:ERIS) Share Price

May 10
Why We're Not Concerned About Eris Lifesciences Limited's (NSE:ERIS) Share Price

An Intrinsic Calculation For Eris Lifesciences Limited (NSE:ERIS) Suggests It's 25% Undervalued

Mar 14
An Intrinsic Calculation For Eris Lifesciences Limited (NSE:ERIS) Suggests It's 25% Undervalued

Analyst Estimates: Here's What Brokers Think Of Eris Lifesciences Limited (NSE:ERIS) After Its Third-Quarter Report

Feb 15
Analyst Estimates: Here's What Brokers Think Of Eris Lifesciences Limited (NSE:ERIS) After Its Third-Quarter Report

Earnings Tell The Story For Eris Lifesciences Limited (NSE:ERIS)

Dec 28
Earnings Tell The Story For Eris Lifesciences Limited (NSE:ERIS)

Eris Lifesciences (NSE:ERIS) Seems To Use Debt Quite Sensibly

Dec 07
Eris Lifesciences (NSE:ERIS) Seems To Use Debt Quite Sensibly

Are Eris Lifesciences Limited (NSE:ERIS) Investors Paying Above The Intrinsic Value?

Nov 11
Are Eris Lifesciences Limited (NSE:ERIS) Investors Paying Above The Intrinsic Value?

Are Eris Lifesciences Limited (NSE:ERIS) Investors Paying Above The Intrinsic Value?

Jul 20
Are Eris Lifesciences Limited (NSE:ERIS) Investors Paying Above The Intrinsic Value?

Does Eris Lifesciences (NSE:ERIS) Have A Healthy Balance Sheet?

Nov 20
Does Eris Lifesciences (NSE:ERIS) Have A Healthy Balance Sheet?

These 4 Measures Indicate That Eris Lifesciences (NSE:ERIS) Is Using Debt Safely

Jun 20
These 4 Measures Indicate That Eris Lifesciences (NSE:ERIS) Is Using Debt Safely

A Look At The Fair Value Of Eris Lifesciences Limited (NSE:ERIS)

Feb 24
A Look At The Fair Value Of Eris Lifesciences Limited (NSE:ERIS)

Is Now The Time To Put Eris Lifesciences (NSE:ERIS) On Your Watchlist?

Dec 28
Is Now The Time To Put Eris Lifesciences (NSE:ERIS) On Your Watchlist?

Here's Why I Think Eris Lifesciences (NSE:ERIS) Might Deserve Your Attention Today

Sep 23
Here's Why I Think Eris Lifesciences (NSE:ERIS) Might Deserve Your Attention Today

If You Like EPS Growth Then Check Out Eris Lifesciences (NSE:ERIS) Before It's Too Late

May 26
If You Like EPS Growth Then Check Out Eris Lifesciences (NSE:ERIS) Before It's Too Late

Eris Lifesciences Limited (NSE:ERIS) Shares Could Be 34% Above Their Intrinsic Value Estimate

Apr 17
Eris Lifesciences Limited (NSE:ERIS) Shares Could Be 34% Above Their Intrinsic Value Estimate

Eris Lifesciences Limited's (NSE:ERIS) Stock Has Fared Decently: Is the Market Following Strong Financials?

Mar 12
Eris Lifesciences Limited's (NSE:ERIS) Stock Has Fared Decently: Is the Market Following Strong Financials?

Does Eris Lifesciences (NSE:ERIS) Deserve A Spot On Your Watchlist?

Feb 25
Does Eris Lifesciences (NSE:ERIS) Deserve A Spot On Your Watchlist?

Why Eris Lifesciences Limited (NSE:ERIS) Is A Dividend Rockstar

Feb 12
Why Eris Lifesciences Limited (NSE:ERIS) Is A Dividend Rockstar

Eris Lifesciences Limited (NSE:ERIS) Analysts Are Pretty Bullish On The Stock After Recent Results

Jan 30
Eris Lifesciences Limited (NSE:ERIS) Analysts Are Pretty Bullish On The Stock After Recent Results

Read This Before Buying Eris Lifesciences Limited (NSE:ERIS) Shares

Jan 17
Read This Before Buying Eris Lifesciences Limited (NSE:ERIS) Shares

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Amit Bakshi rispetto agli utili di Eris Lifesciences?
DataCompenso totaleStipendioGuadagni aziendali
Sep 30 2024n/an/a

₹3b

Jun 30 2024n/an/a

₹4b

Mar 31 2024₹49m₹17m

₹4b

Dec 31 2023n/an/a

₹4b

Sep 30 2023n/an/a

₹4b

Jun 30 2023n/an/a

₹4b

Mar 31 2023₹49m₹17m

₹4b

Dec 31 2022n/an/a

₹4b

Sep 30 2022n/an/a

₹4b

Jun 30 2022n/an/a

₹4b

Mar 31 2022₹46m₹26m

₹4b

Dec 31 2021n/an/a

₹4b

Sep 30 2021n/an/a

₹4b

Jun 30 2021n/an/a

₹4b

Mar 31 2021₹27m₹27m

₹4b

Dec 31 2020n/an/a

₹3b

Sep 30 2020n/an/a

₹3b

Jun 30 2020n/an/a

₹3b

Mar 31 2020₹49m₹18m

₹3b

Dec 31 2019n/an/a

₹3b

Sep 30 2019n/an/a

₹3b

Jun 30 2019n/an/a

₹3b

Mar 31 2019₹49m₹18m

₹3b

Dec 31 2018n/an/a

₹3b

Sep 30 2018n/an/a

₹3b

Jun 30 2018n/an/a

₹3b

Mar 31 2018₹49m₹11m

₹3b

Compensazione vs Mercato: La retribuzione totale di Amit ($USD 563.13K ) è circa la media per le aziende di dimensioni simili nel mercato Indian ($USD 491.59K ).

Compensazione vs guadagni: La retribuzione di Amit è stata coerente con le performance aziendali dell'ultimo anno.

AMMINISTRATORE DELEGATO

Amit Bakshi (49 yo)

18yrs

Mandato

₹48,776,648

Compensazione

Mr. Amit Indubhushan Bakshi serves as Chairman and Managing Director at Eris Lifesciences Limited. Mr. Bakshi has an extensive experience of Indian Pharmaceutical industry and handles Strategic Management...

Gruppo dirigente

NomePosizioneMandatoCompensazioneProprietà
Amit Bakshi
Chairman & MDno data₹48.78m42.85%
₹ 69.6b
Sachin Shah
Chief Financial Officer8.3yrs₹18.01mNessun dato
Krishnakumar Vaidyanathan
Executive Director & COO3.7yrs₹44.85mNessun dato
Gagan Atreja
President of Sales & Marketingno data₹22.05mNessun dato
Inderjeet Negi
Executive Directorno data₹12.40m4.36%
₹ 7.1b
Kaushal Shah
Whole Time Directorno data₹6.99m3.28%
₹ 5.3b
Deepak Kapoor
Senior Vice Presidentno data₹13.72mNessun dato
Milind Talegaonkar
Compliance Officer & Company Secretary8.3yrsNessun datoNessun dato
Vijay Joshi
President Medicalno data₹12.31mNessun dato
Manish Kapoor
Vice Presidentno data₹12.36mNessun dato
Alok Mahajan
Vice Presidentno data₹13.30mNessun dato
Viraj Suvarna
Vice Presidentno data₹15.08mNessun dato

8.3yrs

Durata media

50yo

Età media

Gestione esperta: Il team dirigenziale di ERIS è esperto e expertise (durata media dell'incarico 8.3 anni).

Membri del Consiglio di amministrazione

NomePosizioneMandatoCompensazioneProprietà
Amit Bakshi
Chairman & MD18yrs₹48.78m42.85%
₹ 69.6b
Krishnakumar Vaidyanathan
Executive Director & COO4.1yrs₹44.85mNessun dato
Inderjeet Negi
Executive Director18yrs₹12.40m4.36%
₹ 7.1b
Kaushal Shah
Whole Time Director4.4yrs₹6.99m3.28%
₹ 5.3b
Prashant Gupta
Independent Non-Executive Director6.8yrs₹4.13mNessun dato
Sujesh Vasudevan
Independent Non-Executive Director2.5yrs₹4.05mNessun dato
Kalpana Unadkat
Independent Non-Executive Director4yrs₹4.51mNessun dato
Rajeev Dalal
Independent Non-Executive Director4.1yrs₹4.65mNessun dato

4.3yrs

Durata media

50yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di ERIS sono considerati esperti (durata media dell'incarico 4.3 anni).

Analisi aziendale e situazione dei dati finanziari

DatiUltimo aggiornamento (ora UTC)
Analisi dell'azienda2025/01/30 07:09
Prezzo dell'azione a fine giornata2025/01/30 00:00
Guadagni2024/09/30
Guadagni annuali2024/03/31

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

PacchettoDatiTempisticaEsempio Fonte USA *
Dati finanziari della società10 anni
  • Conto economico
  • Rendiconto finanziario
  • Bilancio
Stime di consenso degli analisti+3 anni
  • Previsioni finanziarie
  • Obiettivi di prezzo degli analisti
Prezzi di mercato30 anni
  • Prezzi delle azioni
  • Dividendi, scissioni e azioni
Proprietà10 anni
  • Top azionisti
  • Insider trading
Gestione10 anni
  • Team di leadership
  • Consiglio di amministrazione
Sviluppi principali10 anni
  • Annunci aziendali

* esempio per i titoli statunitensi, per quelli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più , cliccate qui.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su .

Fonti analitiche

Eris Lifesciences Limited è coperta da 16 analisti. 8 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

AnalistaIstituzione
Prashant NairAmbit Capital
Nitin BhasinAmbit Capital
Harith AhamedAvendus Spark